[{"orgOrder":0,"company":"AusperBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"AHB-137","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AusperBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AusperBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AusperBio \/ Inapplicable"},{"orgOrder":0,"company":"AusperBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"AHB-137","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AusperBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AusperBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AusperBio \/ Inapplicable"},{"orgOrder":0,"company":"AusperBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"AHB-137","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AusperBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AusperBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AusperBio \/ Inapplicable"},{"orgOrder":0,"company":"AusperBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"AHB-137","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AusperBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AusperBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AusperBio \/ Inapplicable"},{"orgOrder":0,"company":"AusperBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"AHB-137","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AusperBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AusperBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AusperBio \/ Inapplicable"},{"orgOrder":0,"company":"AusperBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"AHB-137","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AusperBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AusperBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AusperBio \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by AusperBio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EASL Congress
                          Not Confirmed
                          EASL Congress
                          Not Confirmed

                          Details : AHB-137 is an unconjugated antisense oligonucleotide targeting all HBV RNA, which is being developed for the treatment of patients with chronic hepatitis B.

                          Product Name : AHB-137

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          February 11, 2025

                          Lead Product(s) : AHB-137

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EASL Congress
                          Not Confirmed
                          EASL Congress
                          Not Confirmed

                          Details : AHB-137 is an unconjugated antisense oligonucleotide targeting all HBV RNA, which is being developed for the treatment of patients with chronic hepatitis B.

                          Product Name : AHB-137

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          October 07, 2024

                          Lead Product(s) : AHB-137

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EASL Congress
                          Not Confirmed
                          EASL Congress
                          Not Confirmed

                          Details : AHB-137 is an unconjugated antisense oligonucleotide targeting all HBV RNA, which is being developed for the treatment of patients with chronic hepatitis B.

                          Product Name : AHB-137

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          February 14, 2024

                          Lead Product(s) : AHB-137

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EASL Congress
                          Not Confirmed
                          EASL Congress
                          Not Confirmed

                          Details : AHB-137 is a potential best-in-class, highly potent, pan-genotypic antisense oligonucleotide (ASO) targeting all HBV RNA for the treatment of CHB patients. AHB-137 has shown best-in-class activity in reducing HBsAg across multiple preclinical models.

                          Product Name : AHB-137

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          September 03, 2023

                          Lead Product(s) : AHB-137

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EASL Congress
                          Not Confirmed
                          EASL Congress
                          Not Confirmed

                          Details : AHB-137 is an unconjugated antisense oligonucleotide, which is received FDA Clearance of IND Application of AHB-137 in Chronic Hepatitis B Treatment. he clinical trial in the US is part of a multiregional, randomized, double-blinded, placebo-controlled s...

                          Product Name : AHB-137

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          August 25, 2023

                          Lead Product(s) : AHB-137

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EASL Congress
                          Not Confirmed
                          EASL Congress
                          Not Confirmed

                          Details : AHB-137 is an unconjugated antisense oligonucleotide (ASO) with the potential treatment to be a backbone for the functional cure of Chronic Hepatitis B.

                          Product Name : AHB-137

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          June 28, 2023

                          Lead Product(s) : AHB-137

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank